Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial

Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis

(2020) Lina Marenco-Hillembrand et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

(2020) Patrick Y Wen et al.   NEURO-ONCOLOGY

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus

(2020) Marco Mineo et al.   MOLECULAR CELL

The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection

(2020) Kristen E. Pauken et al.   Cell Reports

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

(2019) William Tomaszewski et al.   CLINICAL CANCER RESEARCH

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

(2019) E. Antonio Chiocca et al.   Science Translational Medicine

Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases

(2018) Surabhi Ranjan et al.   BMC CANCER

Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma

(2018) John A. Barrett et al.   CANCER GENE THERAPY

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

(2018) Frederick F. Lang et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

(2017) Antonio Omuro et al.   NEURO-ONCOLOGY

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

(2017) Lei Qin et al.   NEURORADIOLOGY

T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints

(2017) Reza Mirzaei et al.   TRENDS IN IMMUNOLOGY

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

(2017) Anna C. Filley et al.   Oncotarget

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

(2016) Lee A. Wheeler et al.   NEURO-ONCOLOGY

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

(2016) Timothy F. Cloughesy et al.   Science Translational Medicine

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue

(2013) M. J. Gerdes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity

(2009) H Komita et al.   CANCER GENE THERAPY

A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma

(2008) E Antonio Chiocca et al.   MOLECULAR THERAPY